• Adcendo exercises its options to further expand its ADC pipeline using Bioatuz's fully human antibodies, developing new therapies targeting cancers with high unmet Medical needs.
• This collaboration further validates the potential of Bioatuz's independently developed RenMice antibody discovery platform in promoting innovative therapies that benefit patients.

Peking, December 16, 2024 /PR Newswire/ -- Bioatuz (Peking) Medical Technology Co., Ltd. (Bioatuz, stock code: 02315.HK), an international Biotechnology company focused on the development of new antibody/ADC therapies, announced that Adcendo ApS ("Adcendo"), a Biotechnology company developing the world's first ADC therapies focused on treating cancers and other unmet clinical needs, has exercised its options under a research, selection, and licensing agreement to further expand its ADC pipeline using Bioatuz's fully human antibodies.

Dr. Shen Yulei, Chairman and CEO of Bioatuz, stated: "We are very pleased to support Adcendo's development program in innovative ADC drugs through Bioatuz's advanced antibody discovery platform. Our unique RenMice platform can discover fully human antibodies with high affinity, low immunogenicity, and good developability. Combined with Adcendo's rich experience in the ADC field, we believe this collaboration will accelerate the R&D of innovative therapies, benefiting Global patients."

Michael Pehl, the CEO of Adcendo, stated: "The collaboration with Bioday marks a key step in our development of innovative ADC therapies. Combining the expertise of both parties in ADC development can accelerate the progress of new ADC drug development. This collaboration enhances our technological capabilities, bringing us closer to our goal of providing transformative treatments for cancer patients with high unmet medical needs."

About Bioday

Bioday (Stock code: 02315.HK) is an international biotechnology company driven by innovative technology and dedicated to becoming a global source of new drugs. Based on underlying Gene Editing technology, Bioday has independently developed the RenMice (RenMab, RenLite, RenNano, RenTCR-mimic) platform for discovering fully human therapeutic monoclonal antibodies, bi/multi-specific antibodies, bispecific ADCs, nanobodies, and TCR-like antibodies. Bioday is conducting large-scale drug development on over 1,000 potential druggable targets ("Thousand Mice, Ten Thousand Antibodies TM" program) and has established a library of over 400,000 fully human antibody sequences for global collaboration. As of June 30, 2024, Bioday has signed approximately 150 drug collaboration/development/licensing agreements and has reached nearly 50 target project development collaborations with enterprises, including several MNCs, on the RenMice platform, with several clinical-stage antibody molecules also having external licensing agreements. The company's sub-brand BioMice provides thousands of gene-edited animals and cell models, including target humanized mice, while offering global customers preclinical pharmacology, efficacy, and Gene Editing services. Bioday's headquarters is located in Peking, with branches established in China (Jiangsu Haimen, Shanghai), the USA (Boston, San Francisco), and Heidelberg, Germany. For more information, please visit the official website.

Bioday Contact Information

Antibody Assets and Technology Platform: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn